Contributor Page
Norton Rose Fulbright Canada LLP
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 2164000
Fax: +1 416 2163930
Suite 3800
Royal Bank Plaza, South Tower
200 Bay Street, P.O. Box 84
M5J 2Z4
Contributor Most Read
Contributor Most Read
By Bruce Sheiner
The American Bar Association recently published the 2016 Canadian Private Target M&A Deal Points Study.
By Philippe Bélisle
In the course of the year, it will be interesting to see how the Government of Québec will deal with pay equity matters.
By Dana Carson
S&P 500 companies most frequently (37% of the time) added an executive committee.
By Jonathan Chong, Amy Grenon, Allyson Whyte Nowak
The FCA remitted the matter back to the Federal Court for redetermination, excluding the hearsay evidence.
By Norton Rose Fulbright Canada LLP
On Wednesday, February 1, Norton Rose Fulbright hosted its second annual Motion 2017 – Discussing what matters in Calgary.
By Sam Zadeh
Fuelled by low interest rates, strong corporate balance sheets and stable finances, 2016 was a strong year for Canadian M&A.
By Kristin Wall, Tracey Stott, Chelsea Nimmo
In its February 2017 newsletter, the PMPRB announced its intention to move patented generic drug price reviews to a complaint-based process, similar to the provisions for over-the-counter drug products...
By Rhonda Shirreff
On January 30, 2017, a Board of Inquiry, formed as part of the Provincial Court of Nova Scotia, issued its decision in Skinner v. Board of Trustees of the Canadian Elevator Industry Welfare Trust Fund, which found that the denial of an employee's request for coverage of medical marijuana under a health benefit plan amounted to discrimination under the Nova Scotia Human Rights Act.
By Christopher Guerreiro
The Federal Court awarded accounting of profits and pre-grant compensation for valid and infringed claims of a patent for hot refuelling of fracking equipment, but declined to award punitive damages.
By Sara Josselyn
Global M&A activity in the biopharmaceutical industry skyrocketed in 2014 and 2015, eclipsing US$200 billion in deal value each year and prompting EY to declare such elevated activity...
By Michael Sherman
Deals often come together very quickly. In all that rush, it's easy for the parties to forget to think about all of the long term implications of the deal.
By Ian Trimble, Kristin Wall, Sara Zborovski
Health Canada rejected Apotex's ANDS for a generic version of PROMETRIUM® (progesterone) due to high levels of sodium lauryl sulfate (SLS).
By Trevor Zeyl
On the other hand, the Group takes a skeptical view of a common practice in Canada: dual-class share structures.
By Jonathan Chong, Niall Cooney
The plaintiffs alleged the subsequent delivery of corrected answers effectively robbed them of the opportunity to decide whether to proceed to trial or not, resulting in wasted time and expense.
By Sara Josselyn
Over the past few months, the Canadian government has been working to establish a source of financing for several infrastructure projects across the country.
Contributor's Topics